D-1232-2020 Class II Terminated
FDA drug recall D-1232-2020 was initiated by Aurobindo Pharma USA Inc. on Mar 18, 2020 and is designated Class II. Reason for recall: CGMP Deviations: Products were manufactured in a processing area in which water leakage was observed The recall status is terminated (terminated Mar 25, 2024). Affected quantity: 26625 units.
Recall details
- Product Type
- Drugs
- Report Date
- Apr 22, 2020
- Initiation Date
- Mar 18, 2020
- Termination Date
- Mar 25, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 26625 units
Product description
Gabapentin Capsules, USP 100mg 1,000-count bottles, Rx only, Distributed by: Aurobindo Pharma USA, Inc. Dayton, NJ 08810, NDC 65862-198-99
Reason for recall
CGMP Deviations: Products were manufactured in a processing area in which water leakage was observed
Distribution pattern
Nationwide within the United States
Code information
Lot #: 198180048A, Exp. Date 04/2021; 198180061A, Exp. Date 06/2020; 19819017A1, Exp. Date 02/2021
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1232-2020
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026